Skin Cancer Features Archive

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

Encorafenib Plus Binimetinib Offers a New Option for MEK+BRAF Inhibition

In the immunotherapy era, the optimal setting and sequencing of BRAF+MEK inhibition remains unresolved.

The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

Dr Vorobiof discusses the important patient factors that can be missed via standard data collection methods for those with cancer.

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Predicting Response to Immunotherapy in Late-Stage Melanoma

Predicting Response to Immunotherapy in Late-Stage Melanoma

A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Exploring the Role of Immunotherapy in Melanoma Brain Metastases

Exploring the Role of Immunotherapy in Melanoma Brain Metastases

Although checkpoint inhibitors are active against melanoma-linked brain metastases, researchers are interested in exploring combination approaches.

Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Tapping Social Media for Skin Cancer Prevention: What You Can Do

Tapping Social Media for Skin Cancer Prevention: What You Can Do

Any images and personal stories that remind people about skin cancer, what to look for, even scars after surgery, really help save lives.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma

Next-Generation Sequencing Adds Value by Detecting More Mutations Than Polymerase Chain Reaction in Melanoma

Since next-generation sequencing reflex testing has been implemented at Case Western Reserve University School of Medicine, several cases of potentially actionable mutations have been identified that would not have been caught by PCR alone.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

Novel Targets, Treatments Needed for Melanomas Not Responding to Targeted Immunotherapies

Novel targets in the treatment of melanoma was a hot topic of discussion during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors

In Melanoma, Older Adults Could Benefit More From Treatment With PD-1 Inhibitors

Patient age should play a role in drug development strategies for melanoma, researchers of a new study say.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Marital Status Predicts Melanoma Stage at Diagnosis—But Why?

Marital Status Predicts Melanoma Stage at Diagnosis—But Why?

Married people are more likely than unmarried, divorced, or widowed patients to be diagnosed with skin cancer at early, more readily-treatable stages of disease.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

The Benefits of Adjuvant Immunotherapy in Melanoma

The Benefits of Adjuvant Immunotherapy in Melanoma

KEYNOTE-054 may show whether some patients with resected disease can forego adjuvant therapy.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Late-Onset Toxicity Possible With Immunotherapy

Late-Onset Toxicity Possible With Immunotherapy

Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Interest in Oncolytic Viruses Continues To Grow

Interest in Oncolytic Viruses Continues To Grow

A variety of viruses are being researched in cancers including melanoma, brain tumors, breast cancers, and others.

Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Combining Chemotherapy With Immunotherapy To Improve Response Rates

Combining Chemotherapy With Immunotherapy To Improve Response Rates

The combinatorial approach is not, furthermore, limited to chemotherapy.

Obesity Associated With Improved Melanoma Outcomes

Obesity Associated With Improved Melanoma Outcomes

Some observational studies suggest that overweight BMI may have a protective effect during cancer treatment.

Immunotherapy for Metastatic Melanoma — In the Clinic

Immunotherapy for Metastatic Melanoma — In the Clinic

The management of toxicities and re-initiation of these medications should be made on a case by case basis.

Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

Can Vismodegib Induce Melanoma in Patients Treated for Basal Cell Carcinoma?

Can Vismodegib Induce Melanoma in Patients Treated for Basal Cell Carcinoma?

Two cases raise the question of whether abnormal activation of the hedgehog signaling pathway can lead to a protective effect on melanomas.

Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

AI: Inroads Into Clinical Oncology

AI: Inroads Into Clinical Oncology

Novel algorithms may be able to diagnose and plan cancer treatments more effectively than humans, but it's unclear if and when artificial intelligence will be integrated into clinical practice.

Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

Encorafenib/Binimetinib Combination Shows Promise for Advanced Melanoma

Encorafenib/Binimetinib Combination Shows Promise for Advanced Melanoma

The combination may be an attractive option for some, but further research is needed to target the therapy effectively to particular patients.

Cannabis for Cancer: An Uncertain Future

Cannabis for Cancer: An Uncertain Future

While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.

The Warburg Effect: Can Cancer Be Starved of Sugar?

The Warburg Effect: Can Cancer Be Starved of Sugar?

A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.

Monitoring for Post-organ Transplant Skin Cancer: Patients and Physicians Both Play A Vital Role

Monitoring for Post-organ Transplant Skin Cancer: Patients and Physicians Both Play A Vital Role

As post-transplant medications are used to reduce the body's immune reaction to a foreign organ, they may also reduce the body's ability to accurately survey for malignant cells.

The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma

The Challenges of Immunotherapy Re-challenge in Metastatic Melanoma

It is not always clear whether patients who discontinue anti-PD-1 and -CTLA-4 therapy should re-initiate treatment after adverse events are resolved.

Nano-pulse Stimulation Shows Early Preclinical Promise

Nano-pulse Stimulation Shows Early Preclinical Promise

NPS with electrodes is under investigation as a potential new ablative — and possibly immunotherapeutic — cancer treatment modality.

Genetic Predisposition to Cancer: Where Are We Now?

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.

Mobile Apps: The Future of Cancer Care?

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.

Spontaneous Regression of Cancer: Explanations and Predictions

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma

PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma

Researchers found that cells resistant to both BRAF inhibition and combination inhibition were sensitive to PAK inhibition, and further that PAK inhibition slowed cell-cycle progression.

Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma

Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma

Mario Sznol, MD, of the Yale University School of Medicine in New Haven, Connecticut, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.

Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma

Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma

Ongoing trials, including those that combine immunotherapy with BRAF inhibitors or a triple combination of an anti-PD-1 antibody with BRAF and MEK inhibitors, may provide more options to patients.

Timing Targeted and Immunotherapies for Metastatic Melanoma

Timing Targeted and Immunotherapies for Metastatic Melanoma

Treatment options for metastatic melanoma are evolving rapidly — creating uncertainties about the best strategies for sequencing targeted and immunotherapeutic agents.

Establishing Links Between Germline Mutations and Oncogenesis

Establishing Links Between Germline Mutations and Oncogenesis

In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Should Nicotinamide Be Used for Melanoma Prevention?

Should Nicotinamide Be Used for Melanoma Prevention?

Nicotinamide, a form of vitamin B3 (niacin), may be an effective chemopreventive agent for patients at high risk for developing skin cancer

Knowledge of Immunotherapies in Melanoma Continues to Grow

Knowledge of Immunotherapies in Melanoma Continues to Grow

Clinicians continue to learn about which patients will benefit most from different immunotherapy treatments, and how dosing can effect adverse events.

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

Melanoma Vaccine Trial Yields Promising Results

Melanoma Vaccine Trial Yields Promising Results

Developments in deep sequencing genomic technologies and bioinformatics have made it possible to identify mutations in melanoma and to predict targetable neoantigens.

Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

Intratumoral IL-12 Electroporation for Melanoma

Intratumoral IL-12 Electroporation for Melanoma

Intratumoral, or intralesional, therapies are injected directly into the tumor, but can have systemic effects such that some non-injected lesions demonstrate regression.

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

Dermatomyositis and Cancer Risk

Dermatomyositis and Cancer Risk

Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.

Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?

Q&A With Keith Flaherty, MD: Dabrafenib and Trametinib for Melanoma

Q&A With Keith Flaherty, MD: Dabrafenib and Trametinib for Melanoma

Cancer Therapy Advisor interviewed Keith Flaherty, MD, about recent findings regarding targeted therapies for melanoma.

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.

Immune Checkpoint Inhibitors: Treatment Efficacy in Elderly Patients With Melanoma

Immune Checkpoint Inhibitors: Treatment Efficacy in Elderly Patients With Melanoma

Immune checkpoint inhibitors may be effective for treating elderly patients with melanoma without dramatically increasing toxicity.

Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinicians are evaluating how to best preserve the reproductive potential of survivors.

Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity

Pembrolizumab for Advanced Melanoma: Efficacy and Toxicity

This PD-1 inhibitor is effective for treating melanoma, though it can be highly toxic and there is a lack of biomarkers for predicting a response.

Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

Avelumab: A Landmark Approval in Metastatic Merkel Cell Carcinoma

Avelumab: A Landmark Approval in Metastatic Merkel Cell Carcinoma

This approval is likely to dramatically improve the otherwise dismal outcomes for patients in this clinical setting.

Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Immunotherapy in the Twentieth Century: William Coley and Lloyd J. Old

Dr Clifford Pukel, a board certified medical oncologist and CEO of the Cancer Vaccine Cancer Immunotherapy (CVCI) foundation, discusses some important moments in the history of immunotherapy.

Incorporating Evolutionary Theory Into Oncology

Incorporating Evolutionary Theory Into Oncology

Oncologists, drug developers, and evolutionary theorists could collaborate to design treatments and treatment combinations that are more likely to succeed given the laws of natural selection.

Industry Payments Influence Research, Prescribing, and Advocacy

Industry Payments Influence Research, Prescribing, and Advocacy

Clinical trial investigators who receive drug industry funding are about 3.5 times as likely to find positive results as trials led by scientists who did not receive industry payments.

Treeomics: A Mathematical Tool for Predicting Metastases

Treeomics: A Mathematical Tool for Predicting Metastases

Researchers recently created a tool, Treeomics, to reconstruct the evolutionary pathway of metastases and to chart subclones to their anatomical locations.

Melanoma: The State and Future of Treatment

Melanoma: The State and Future of Treatment

Melanoma treatment has improved dramatically in the past decade, and new advancements are already on the horizon.

ASCO Advance of the Year: Immunotherapy 2.0

ASCO Advance of the Year: Immunotherapy 2.0

The American Society of Clinical Oncology (ASCO) named Immunotherapy 2.0 the "advance of the year."

Melanoma: A Need for Specialty Clinics

Melanoma: A Need for Specialty Clinics

Specialized treatment centers would bring together oncology faculty capable of managing the administration of drugs, including immunotherapies.

The 21st Century Cures Act: An Unclear Advance

The 21st Century Cures Act: An Unclear Advance

Critics worry that changes to the FDA's drug approval process could lead to increased off-label prescribing and the marketing of questionable therapies.

SN-MMR for Stratification of SNB-positive Melanoma

SN-MMR for Stratification of SNB-positive Melanoma

SN-MMR was strongly associated with OS, melanoma-specific survival, and DFS among patients with a positive sentinel node biopsy.

Vitamin D and Cancer: An Unclear Relationship

Vitamin D and Cancer: An Unclear Relationship

According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.

Basket Trials: Advantages and Limitations

Basket Trials: Advantages and Limitations

Basket trials offer a cost-effective option to evaluate targeted agents in multiple malignancies, but it is important to be aware of their limitations.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs